Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2002 Apr;2(2):161-8.

ZD1839 (IRESSA): a selective EGFR-TK inhibitor.

Author information

1
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, UK. malcolm.ranson@amn.ac.uk

Abstract

The recent development of highly selective, target-based cancer therapeutics, such as ZD1839 has resulted from a greater understanding of tumor biology. Amongst the most promising of new target-based agents are inhibitors of the epidermal growth factor receptor. ZD 1839 is a potent, selective epidermal growth factor receptor tyrosine kinase inhibitor that has demonstrated promising results in early clinical trials.

PMID:
12113238
DOI:
10.1586/14737140.2.2.161
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center